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17, 2010)Although discovery of the tyrosine kinase inhibitor (TKI) imatinib
mesylate has significantly improved the prognosis of chronic
myeloid leukemia (CML) patients, a rare population of CML stem
cells is known to be resistant to TKI therapy, causing recurrence
of CML. However, recent progress in CML stem cell biology may
present a novel therapeutic avenue for CML patients. In this
review, we focus on mechanisms used by CML stem cells to main-
tain TKI-resistance. Comprehensive approaches including mouse
genetics, prospective identification of CML stem cells, and
syngenic transplantation techniques have identified several key
molecules or signaling pathways, including hedgehog (Hh) ⁄ Smo,
promyelocytic leukemia (PML), 5-lipoxygenase (5-LO), and fork-
head box class O (FOXO), that function in CML stem cell mainte-
nance. Inhibiting some of these factors in combination with TKI
administration successfully antagonized resistance of CML stem
cells to TKI therapy, resulting in efficient eradication of leukemia
cells in vivo. Thus, development of methods that sensitize CML
stem cells to TKI therapy may lead to novel therapies to treat
CML patients. (Cancer Sci 2010; 101: 1577–1581)3To whom correspondence should be addressed.
E-mail: ahirao@kenroku.kanazawa-u.ac.jpChronic Myeloid Leukemia (CML) as a ‘‘Stem Cell Disease’’
H ematopoietic stem cells (HSCs), which top the hierarchyof the normal hematopoietic system, are defined by both
their ability to reproduce themselves, a property known as self-
renewal, and their capacity to give rise to all mature hematopoi-
etic cell lineages throughout an individual’s lifetime. Recently,
it was revealed that CML contains leukemia stem cells which
form a hierarchy similar to that seen in normal hematopoiesis.
Human CML is a biphasic myeloproliferative disease (MPD),
which initially assumes a chronic phase before progressing to an
accelerated phase and then to blast crisis. In CML patients, the
initial chronic phase is characterized by massive expansion of
myeloid cells. Fialkow et al.(1) demonstrated that chronic phase
CML cells can produce functionally normal mature blood cells,
indicating that CML cells in the chronic phase can differentiate
into mature blood cells, like normal HSCs. Acquisition of addi-
tional genetic mutations and ⁄or epigenetic alterations results in
progression from the chronic phase to an accelerated phase and
finally to blast crisis. Indeed, Jamieson et al.(2) proposed a
model in which abnormal activation of b-catenin in a granulo-
cyte ⁄macrophage progenitor (GMP)-like population in CML
patients promotes disease progression from chronic phase to
blast crisis. Blast crisis is characterized by accumulation of mye-
loid or lymphoid blast cells in peripheral blood or bone marrow,doi: 10.1111/j.1349-7006.2010.01584.x
ª 2010 Japanese Cancer Associationindicating that CML cells in blast crisis can proliferate but that
their differentiation capacity is blocked. Since CML patients in
blast crisis show poor prognosis with short survival, it is critical
to treat CML patients during the chronic phase.
Most CML is caused by a translocation between human
chromosomes 9 and 22 that generates what is known as the Phila-
delphia chromosome and resultant breakpoint cluster region-
abelson (BCR–ABL) fusion gene, which encodes a constitutively
active tyrosine kinase.(3) Several lines of evidence indicate that
CML cells emerge due to expression of BCR–ABL in normal
HSCs (Fig. 1). Transplantation of multipotent murine HSCs
expressing BCR–ABL into recipient mice induces CML-like
MPD.(4–8) By contrast, CML is not induced in committed murine
hematopoietic progenitor cells expressing BCR–ABL.(9) These
results demonstrate that chronic phase CML cells originate from
multipotent HSCs. In a mouse CML-like MPD model, CML
stem cells, which are defined by the ability to induce CML in
transplanted mice, can be purified in a rare c-Kit+Lineage)
Sca-1+ (KLS+) population of mouse CML cells (i.e. in cells that
exhibit the marker profile of normal HSCs).(10–14) Interestingly,
in human CML patients, CML stem cells are apparently found
in a cell fraction expressing cell surface markers characteristic
of primitive hematopoietic cells.(15,16) All of these findings
support the notion that CML is a ‘‘stem cell disease’’ (Fig. 1).
In this review, we present evidence from our investigations
and those of others supporting a link between molecular mech-
anisms regulating self-renewal in normal HSCs and CML stem
cells, and discuss current efforts aimed at developing novel
therapeutics to specifically target tyrosine kinase inhibitor
(TKI)-resistant CML stem cells.
Common Signaling Pathways Underlie Stem Cell Fate
in Both Normal Hematopoiesis and CML
Observation that HSCs and CML stem cells share common
properties suggests that signaling pathways determining nor-
mal HSC fate also govern maintenance of CML stem cell
function. Several factors regulating stem cell fate in both nor-
mal hematopoiesis and CML leukemogenesis have been identi-
fied (Fig. 1). Promyelocytic leukemia (PML) protein functions
in diverse cellular activities, including the DNA damage
response, apoptosis, cellular senescence, and neoangiogene-
sis.(17) Ito et al.(12) found that PML is highly expressed in nor-
mal HSCs and that Pml deficiency impairs HSC self-renewalCancer Sci | July 2010 | vol. 101 | no. 7 | 1577–1581
Fig. 1. A link between molecular mechanisms regulating self-renewal activity in normal hematopoietic stem cells (HSCs) and in chronic myeloid
leukemia (CML) stem cells. HSCs, which top the hierarchy of the normal hematopoietic system, are defined by both their ability to self-renew
and to give rise to all lineages of mature hematopoietic cells throughout an individual’s lifetime. A rare population of CML stem cells also can
self-renew and generate progenitor-like and differentiated CML cells, indicating that CML cells in the chronic phase form a hierarchy similar to
that of normal HSCs. Several lines of evidence demonstrate that the emergence of CML cells requires BCR–ABL expression in normal HSCs.
Recently molecules regulating normal HSC fate, including promyelocytic leukemia (Pml), Smo, and forkhead box class O (Foxo)-3a, have also
been shown to govern CML stem cell function. These observations support the idea that CML is ‘‘stem cell disease’’.
Table 1. The biology and TKI-resistance in CML stem cells based on mouse genetic studies
Disrupted
molecule
CML stem cells Inhibitor Possible combined therapy Reference
Pml Defective ability of CML stem
cells to develop CML at third transplantation
Arsenic trioxide Arsenic trioxide and Ara-C improve
survival of CML-affected mice
12
b-Catenin Defective ability of CML stem cells
to develop CML at second transplantation
– – 11
Alox5 Defective ability of CML stem cells
to develop CML at second transplantation
Zileuton Zileuton and imatinib improve
survival of CML-affected mice
45
Smo Impairment of development of CML and
depletion of CML stem cells
Cyclopamin Cyclopamin and nilotinib prolong
survival of CML-affected mice
13,21
Foxo3a Defective ability of CML stem cells to develop
CML at third transplantation
TGF-b inhibitor TGF-b inhibitor and imatinib
improve survival of CML-affected mice,
and suppress infiltration of CML cells in lung
14
Arsenic trioxide can reduce PML expression. Zileuton is an inhibitor of 5-lipoxygenase. Cyclopamin stabilizes Smo in an inactive form. TGF-b
inhibitor suppresses TGF-b–Foxo signaling. Alox5, arachidonate 5-lipoxygenase; CML, chronic myeloid leukemia; Foxo3a, forkhead box class O 3a;
PML, promyelocytic leukemia; TGF-b, transforming growth factor-b.capacity. Importantly, whereas Pml+ ⁄+ CML stem cells main-
tain the ability to induce CML at least at the 4th-serial trans-
plantation, Pml) ⁄ ) CML stem cells fail to generate disease at
the 3rd-transplantation, demonstrating that PML is essential
for CML stem cell maintenance (Table 1). Since in vivo treat-
ment with arsenic trioxide (As2O3), which can reduce PML
expression, eradicates CML stem cells in combination with
the anti-leukemia drug Ara-C, PML down-regulation is an
important candidate for CML stem cell-targeting therapy.
Wnt ⁄b-catenin signaling is implicated in both normal HSC
homeostasis and CML leukemogenesis. b-Catenin reportedly
functions to regulate normal mouse HSC self-renewal.(11,18,19)
Interestingly, Zhao et al.,(11) reported that conditional deletion
of b-catenin impairs long-term maintenance of CML stem cells
in the chronic phase, whereas loss of b-catenin allows acute
lymphoblastic leukemia (ALL) to proceed unimpaired (Table 1).
Loss of b-catenin can suppress infiltration of CML cells into the
lung and liver in mice injected with CML stem cells. Thus,
Wnt ⁄b-catenin signaling likely plays a role in maintaining CML
stem cells.
Hedgehog (Hh) signaling reportedly regulates self-renewal of
normal HSCs and CML stem cells. In the absence of Hh ligands,1578the 12-pass transmembrane domain receptor Patched (Ptch)
inhibits Smo, a seven-pass transmembrane domain receptor.(20)
Binding of Hh ligands, including Sonic hedgehog (Shh), Indian
hedgehog (Ihh), and Desert hedgehog (Dhh), to Ptch activates
Smo, which in turn activates signaling via Gli transcriptional
effectors. To understand the role of Hh signaling in normal
HSCs and CML leukemogenesis, Dierks et al. and Zhao
et al.(13,21) in parallel studies analyzed the effects of conditional
Smo deletion in the hematopoietic system. Although the fre-
quency of normal HSCs was unchanged in Smo-deficient
mice,(13,21) Smo was required for long-term maintenance of
HSCs in vivo.(13) Interestingly, Smo loss causes CML stem cell
depletion and impairs CML development,(13,21) whereas expres-
sion of constitutively active Smo increases the frequency of
CML stem cells and accelerates CML development.(13) These
findings demonstrate that Hh signaling plays an essential role to
maintain CML stem cell function.
Forkhead box class O (FOXO) transcription factors also play
an important role in the maintenance of normal HSCs and CML
stem cells. The FOXO factors include FOXO1, FOXO3a,
FOXO4, and FOXO6, all of which are downstream targets of
Phosphatidylinositol 3 kinase (PI3K)–AKT signaling.(22) In thedoi: 10.1111/j.1349-7006.2010.01584.x
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absence of stimulation by growth factors or insulin, FOXOs are
present in the nucleus and activate their transcriptional targets.
When a growth factor or insulin binds to the appropriate cell
surface receptor, AKT is activated and directly phosphorylates
FOXOs, resulting in their nuclear exclusion and degradation in
the cytoplasm. Tothova et al.(23) reported that in mice with triple
conditional deletion of Foxo1, Foxo3a, and Foxo4, the HSC
population markedly increases. We and others have reported
that Foxo3a alone is essential to maintain the HSC pool,(24,25)
indicating that FOXOs are essential to maintain normal HSC
self-renewal. Recently, we demonstrated an essential role for
Foxo3a in the maintenance of CML stem cells.(14) Previous
studies using CML cell lines indicate that BCR–ABL likely
activates PI3K–AKT signaling, leading to FOXO nuclear export
and suppression of FOXO transcriptional activity.(26–28) How-
ever, using a mouse CML-like MPD model we found that
whereas non-CML stem cells showed high levels of Akt phos-
phorylation and cytoplasmic localization of Foxo3a, cells with
decreased Akt phosphorylation and nuclear localization of
Foxo3a were enriched in the CML stem cell population, despite
expression of BCR–ABL. We also showed that the ability of
CML stem cells to promote disease at the 3rd-transplantation is
significantly decreased by Foxo3a deficiency in vivo. In particu-
lar, cells deficient in Foxo3a lose the potential to generate
malignancies in multiple lineages.(14) Thus, Foxo3a is essential
for long-term maintenance of leukemia-initiating potential in
CML stem cells.
Resistance of Quiescent CML Stem Cells to TKI Therapy
The development of imatinib mesylate, an inhibitor of ABL
kinase, has represented a breakthrough in CML treatment.(29)
However, most CML patients require additional therapy due to
resistance or intolerance.(30–33) Recent studies report that TKIs
including imatinib, nilotinib, and dasatinib are potent TKI inhib-
itors in differentiated CML cells but are not as effective in qui-
escent primitive CML stem cells (Fig. 2).(34–39) In addition,
mathematical modeling has shown that successful imatinib ther-Fig. 2. Residual CML stem cells are responsible for TKI resistance in CM
ABL fusion protein. The TKI imatinib, which inhibits ABL tyrosine kina
numerous CML cells, such as progenitor-like CML cells and differentiated
in the chronic phase. However, it does not deplete CML stem cells, whi
Thus, effective human CML therapy requires measures to eradicate TKI-
cells.
Naka et al.apy is characterized by a bi-phasic, exponential decline in the
number of CML cells, but that imatinib likely does not deplete
CML stem cells in patients in the chronic phase.(40,41) Since
residual CML stem cells are the source of disease recurrence,
drugs capable of eradicating CML stem cells would provide
markedly improved therapeutic benefits to CML patients.(42)
Molecular Mechanisms of TKI-Resistance of CML Stem
Cells
Several potential mechanisms underlying TKI-resistance of
CML stem cells have been proposed. It has been shown that
CML stem cells are quiescent and undifferentiated, resulting
in resistance to chemotherapy. CML stem cell properties are
possibly regulated by association with a niche. Several lines of
evidence indicate that inactivation of key molecules for CML
stem cell maintenance possibly contributes to development of
CML therapy. For example, pharmacological blockade of Hh
signaling by cyclopamine, which stabilizes Smo in an inactive
form, impairs CML development by CML stem cells
(Table 1).(13,21) Furthermore, combining a TKI (nilotinib) with
cyclopamine increased the amount of time to disease recurrence
more effectively than did treatment with a TKI alone.(21)
BCR–ABL drives robust AKT activation, which represses
FOXO function. TKIs block this activity and promote FOXO
nuclear localization and activation, which induces apoptosis or
cell cycle arrest. However, as noted above we observed unex-
pected nuclear localization of FOXO in CML stem cells in
mouse models.(14) Since CML stem cells resist TKI therapy, it is
suggested that this ‘‘stem cell paradox’’ regarding FOXO acti-
vation may reflect stem cell status. Komatsu et al. previously
reported that introduction of an activated form of FOXO into the
CML line KCL22 led to cell cycle arrest, concluding that
FOXO3a is a downstream effector of TKI-induced cell cycle
arrest in CML cells. This study also reported the interesting find-
ing that FOXO inactivation sensitizes cells to TKI treatment
in vitro, suggesting that FOXO contributes to resistance to TKI
therapy. To address whether FOXO functions as a TKI effectorL patients. CML arises in HSCs due to activity of the oncogenic BCR–
se activity, is now standard therapy for CML. Imatinib can eradicate
CML cells, and significantly improves the prognosis of CML patients
ch top the CML hierarchy and are responsible for disease recurrence.
resistant CML stem cells. Ph+, Philadelphia chromosome-positive CML
Cancer Sci | July 2010 | vol. 101 | no. 7 | 1579
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Fig. 3. Possible strategy to eradicate chronic CML cells by inhibiting association of CML stem cells with their niche. Although imatinib can
eradicate numerous TKI-sensitive differentiated CML cells, it does not deplete CML stem cells responsible for disease recurrence. Interaction of
TKI-resistant CML stem cells with a niche may keep stem cells dormant and undifferentiated. Thus, inhibitors of the niche signal could activate
cell cycling or induce differentiation, promoting TKI-sensitivity. Together, factors capable of inhibiting CML stem cell ⁄ niche interaction are
important candidates for CML therapies.or an inhibitor of TKI in CML stem cells in vivo, we investi-
gated roles of Foxo3a in response to TKI therapy using a CML
mouse model.(14) We found that Foxo3a deficiency enhanced
sensitivity of CML stem cells to TKI therapy and proposed that
Foxo3a plays distinct roles in CML stem cells versus non-CML
stem cells.(14) In our model, FOXO activation protects CML
stem cells against various stresses, including TKI therapy,
whereas it induces apoptosis or cell cycle arrest in non-CML
stem cells in response to TKI therapy.
We have also searched for chemical compounds that alter
Akt–Foxo status in CML stem cells and found that treatment
of CML stem cells with Ly364947, an inhibitor of transform-
ing growth factor (TGF)-b signaling, efficiently activates Akt
and suppresses Foxo. Although administration of Ly364947
alone did not extend the survival of CML-affected mice,
Ly364947 combined with imatinib significantly reduced reci-
pient lethality and decreased CML stem cell frequency
(Table 1).(14) These in vivo data demonstrate a critical role for
the TGF-b ⁄FOXO axis in maintenance of imatinib-resistant
CML stem cells. Interestingly, Yamazaki et al.(43) reported
that TGF-b is a candidate niche factor to maintain HSC dor-
mancy. Thus the TGF-b pathway may be common to both
normal HSCs and CML stem cells. However, we found that
inhibition of TGF-b had a more potent effect on CML stem
cells than on normal stem ⁄progenitor cells.(14) Supporting this
finding, it has been reported that TGF-b signaling is enhanced
by the presence of BCR–ABL.(44) These data indicate that
inhibition of TGF-b signaling may lead to efficient eradication
of residual CML stem cells.
Chen et al.(45) propose an alternate mechanism underlying
TKI resistance of CML stem cells. The Arachidonate 5-lipoxy-
genase (5-LO) gene (Alox5) encodes a lipoxygenase, which
plays a role in the synthesis of leukotrienes from arachidonic
acid and functions in numerous physiological and pathological
processes, including oxidative stress, inflammation, and can-
cer.(46,47) Gene expression profiling revealed that Alox5 expres-
sion is specifically up-regulated by BCR–ABL.(45) Whereas
recipient mice transplanted with Alox5+ ⁄+ CML stem cells died
of CML, mice transplanted with Alox5) ⁄ ) CML stem cells sur-
vived, indicating that Alox5 deficiency underlies impaired CML
stem cell function. Combined administration of the 5-LO inhibi-
tor Zileuton with imatinib prolonged survival of CML-affected
mice (Table 1).(45) Since loss of Alox5 does not affect normal
HSC self-renewal, combined therapy of TKIs and 5-LO inhibi-
tors may bring therapeutic benefits to CML patients in the1580chronic phase. Interestingly, Alox5 up-regulation was not inhib-
ited by TKI treatment, which may explain why imatinib does
not inhibit CML stem cells. Further investigation regarding
BCR–ABL functions not affected by TKI treatment are required
in order to understand mechanisms of TKI-resistance in CML
stem cells.
Although interferon (IFN)-a was a first line treatment for
CML, imatinib has replaced IFN-a therapy due to the higher
response rate. However, it was reported that patients previously
exposed to IFN-a showed a high rate of long-term complete
remission.(48) Interestingly, it has been recently demonstrated
that type I IFNs act directly on HSCs to induce cell cycle
progression,(49,50) suggesting the possibility that IFN-a pre-
treatment sensitized the CML stem cells to TKI therapy. Investi-
gation of the IFN signaling on CML stem cells may influence
the future treatment of CML.
Future Perspectives
In this review, we have focused on recent advances in our under-
standing of CML stem cell maintenance. Notably, factors regu-
lating normal HSCs also govern TKI-resistance in CML stem
cells, indicating that identifying molecular mechanisms govern-
ing normal HSC fate could shed light on activities of CML stem
cells. For instance, inhibiting the association between CML stem
cells and their microenvironment, or niche, could constitute one
therapeutic strategy whereby CML patients could be treated by
specific suppression of TKI-resistant CML stem cells (Fig. 3).
Since normal HSCs are supported within a niche, TKI-resistant
CML stem cells may also be protected and maintained in a dor-
mant, undifferentiated state by interaction with their niche.
Thus, inhibitors of niche signals could promote TKI-sensitive
phenotypes in CML stem cells by activating cell cycling or
inducing differentiation, leading to eradication of CML cells.
Continued investigations of differences between normal HSCs
and CML stem cells are also critical for development of CML
therapy that does not promote severe side effects due to damage
to normal HSCs. Further progress in stem cell biology offers
promising directions for development of successful CML thera-
pies.
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